Charlotte M. N. Allerton
Charlotte M. N. Allerton has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
David Ellis
2 shared publicationsCharlotte A. L. Lane
Discovery Chemistry, Pharmacokinetics, Dynamics and Metabolism, Lead Discovery, and Discovery Biology, Pfizer Global Research & Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
1 shared publicationChristopher G. Barber
Discovery Chemistry, Pharmacokinetics, Dynamics and Metabolism, Lead Discovery, and Discovery Biology, Pfizer Global Research & Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
1 shared publicationColin M. Robinson
Discovery Chemistry, Pharmacokinetics, Dynamics and Metabolism, Lead Discovery, and Discovery Biology, Pfizer Global Research & Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
1 shared publicationDavid G. Brown
Discovery Chemistry, Pharmacokinetics, Dynamics and Metabolism, Lead Discovery, and Discovery Biology, Pfizer Global Research & Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
1 shared publicationDavid Hepworth
Department of Medicine Design, Pfizer Inc., 610 Main Street, Cambridge, MA 02139, USA
1 shared publication
Latest Publications
- Open Access
- 1 February 2022
- Published by Elsevier in Drug Discovery Today
- Vol. 27 (2) , 538-546
Designing small molecules for therapeutic success: A contemporary perspective
- 1 February 2022
- Published by Elsevier in Drug Discovery Today
- Vol. 27 (2) , 538-546
Open AccessDesigning small molecules for therapeutic success: A contemporary perspective
- 1 October 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (19) , 5791-5795
Design and synthesis of pyridazinone-based 5-HT2C agonists
- 1 October 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (19) , 5791-5795
Design and synthesis of pyridazinone-based 5-HT2C agonists
- 24 May 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (12) , 3581-3594
A Novel Series of Potent and Selective PDE5 Inhibitors with Potential for High and Dose-Independent Oral Bioavailability
Sildenafil (5-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one), a potent and selective phosphodiesterase type 5 (PDE5) inhibitor, provided the first oral treatment for male erectile dysfunction. The objective of the work reported in this paper was to combine high levels of PDE5 potency and selectivity with high and dose-independent oral bioavailability, to minimize the impact on the Cmax of any interactions with coadministered drugs in the clinic. This goal was achieved through identification of a lower clearance series with a high absorption profile, by replacing the 5‘-piperazine sulfonamide in the sildenafil template with a 5‘-methyl ketone. This novel series provided compounds with low metabolism in human hepatocytes, excellent caco-2 flux, and the potential for good aqueous solubility. The in vivo oral and iv pharmacokinetic profiles of example compounds confirmed the high oral bioavailability predicted from these in vitro screens. 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (2) was selected for progression into the clinic.
- 24 May 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (12) , 3581-3594
A Novel Series of Potent and Selective PDE5 Inhibitors with Potential for High and Dose-Independent Oral Bioavailability
Sildenafil (5-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one), a potent and selective phosphodiesterase type 5 (PDE5) inhibitor, provided the first oral treatment for male erectile dysfunction. The objective of the work reported in this paper was to combine high levels of PDE5 potency and selectivity with high and dose-independent oral bioavailability, to minimize the impact on the Cmax of any interactions with coadministered drugs in the clinic. This goal was achieved through identification of a lower clearance series with a high absorption profile, by replacing the 5‘-piperazine sulfonamide in the sildenafil template with a 5‘-methyl ketone. This novel series provided compounds with low metabolism in human hepatocytes, excellent caco-2 flux, and the potential for good aqueous solubility. The in vivo oral and iv pharmacokinetic profiles of example compounds confirmed the high oral bioavailability predicted from these in vitro screens. 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (2) was selected for progression into the clinic.